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Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal
cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved.
Hypothesis/Objectives: Observational study to characterize cardiovascular morbidity and survival
in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopa-
thy and in apparently healthy cats (AH).
Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578
preclinical HOCM; 722 AH).
Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were fol-
lowed through medical record review and owner or referring veterinarian interviews. Data were
analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF),
arterial thromboembolism (ATE), and cardiovascular death.
Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death
in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was
7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardio-
vascular death, respectively. There were no statistically significant differences between HOCM
compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to develop-
ment of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had
short survival (mean6 standard deviation, 1.361.7 years). Overall, prolonged longevity was
recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years.
Conclusions and Clinical Importance: Preclinical HCM/HOCM is a global health problem of cats
that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the
need to identify therapies and monitoring strategies that decrease morbidity and mortality.
K E YWORD S
arterial thromboembolism, asymptomatic, congestive heart failure, epidemiology, incidence, out-
come, survival
1 | INTRODUCTION
Cardiomyopathies are the principal cause of cardiovascular morbidity
and mortality in cats,1–6 and hypertrophic cardiomyopathy is the most
common of these disorders.6–29 Although the majority of affected cats
are assumed to remain preclinical (ie, free of clinical signs), a proportion
experiences serious complications, chief among which are congestive
heart failure (CHF), arterial thromboembolism (ATE), and sudden car-
diac death (SD).2,5,7–9,15–20,25,26,28 Certain breeds including Maine
Coon, Ragdoll, British shorthair, Sphynx, Chartreux, Persian, Domestic
Shorthair, and Norwegian Forest Cats are predisposed to hypertrophic
cardiomyopathy, suggesting a heritable basis in these
populations.10–12,24,29–38 Despite the fact that this disease is widely
recognized, risk of attendant cardiovascular complications is unknown,
and the natural history of preclinical feline hypertrophic cardiomyopa-
thy remains unresolved.
Many phenotypic and clinical characteristics of feline hypertrophic
cardiomyopathy, including a highly variable disease course, closely
resemble those reported in humans.2,7–9,15,21–26,28,29 Whereas the
obstructive form of the disease (HOCM) in humans is a major determi-
nant of negative outcome including progressive cardiovascular
disability,39–48 equivalent risk has not been established in affected cats.
Nevertheless, by inference drawn from data in humans, the notion has
lingered that HOCM confers a similar negative prognosis in cats and,
by extension, signifies a target for pharmacotherapy.49
Descriptions of cardiovascular complications in cats with hyper-
trophic cardiomyopathy have originated predominantly from single-site
referral centers.5,7,9,17–20,25,26,28,29 Although informative, such results
tend to concentrate severely affected cases and are subject to tertiary
center referral bias. This can lead to overstating adverse outcomes and
fosters the impression that the disease is dominated by pessimistic out-
come.46 Furthermore, combining preclinical and heart failure patient
data limits risk estimation and prognosis for cats having only preclinical
disease.5,7,9,14,17,26,28
Thus, to understand the natural history of preclinical hypertrophic
cardiomyopathy, we conducted a long-term multicenter, epidemiologic
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study to evaluate large cohorts of affected and nonaffected cats in
many different countries around the world. This approach permitted us
to identify and compare incidence and risk for cardiovascular morbidity,
mortality, and survival characteristics among these populations.
2 | MATERIALS AND METHODS
2.1 | Study design
The “International collaborative study to assess cardiovascular risk and
evaluate long-term health in cats with preclinical hypertrophic cardio-
myopathy and apparently healthy cats: The REVEAL Study” was a ret-
rospective, longitudinal, cohort study. An ethical review committee
granted approval where required. Investigators were board-certified
veterinary cardiologists, or in countries without a certification process,
focused on specialty cardiology practice. Each study site had a search-
able echocardiographic and medical record database permitting
detailed review and long-term health follow-up.
2.2 | Cats
Cat populations included preclinical obstructive (HOCM) and nonob-
structive (HCM) forms of hypertrophic cardiomyopathy, and apparently
healthy cats (AH). The term preclinical denoted a physical condition
characterized by lack of clinical signs or manifestations and would be
referred to as “asymptomatic” in human medicine. All AH were exam-
ined by echocardiography, had unremarkable medical history, no
known illness, and had normal physical examination findings without
gallop heart sounds at the point of study entry. Some had been exam-
ined by echocardiography due to presence of a systolic heart murmur,
but those with a systolic heart murmur, trivial mitral or tricuspid valve
regurgitation, or dynamic right ventricular (RV) outflow tract obstruc-
tion were included, provided that the echocardiogram was otherwise
normal.
2.2.1 | Inclusion criteria
Medical records were searched for cats diagnosed with preclinical
hypertrophic cardiomyopathy (both HCM and HOCM) as well as AH
free of cardiomyopathy, the health outcomes of which could be ascer-
tained for at least 5 years after initial diagnosis. Archived echocardio-
graphic images were examined to confirm diagnosis and
measurements. Study entry represented the date when echocardio-
graphic examination was first made.
2.2.2 | Exclusion criteria
Cats were not included in the study if echocardiograms were of non-
diagnostic quality, or if any of the following conditions were diagnosed
at or before study entry: CHF, ATE, syncope, heartworm disease, sys-
temic arterial hypertension (defined as acute neurologic signs or retinal
changes consistent with systemic hypertension, or when measured sys-
tolic arterial blood pressure [SBP]180 mm Hg), hyperthyroidism, ane-
mia, renal disease (either serum creatinine concentration above
laboratory reference range, urine concentrating ability deemed to be
inadequate, or proteinuria), cardiomyopathy other than hypertrophic
cardiomyopathy, congenital heart disease, or any underlying medical
disease judged to be capable of limiting life expectancy. All cardiovas-
cular medications prescribed before or at study entry were recorded,
but were not considered as exclusion criteria.
2.3 | Study sites
Investigators worked at 50 veterinary centers in 21 countries: 22 cen-
ters in 17 states of the United States of America (California, Colorado,
Florida, Indiana, Iowa, Kansas, Louisiana, Massachusetts, Minnesota,
Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas, Vir-
ginia, and Wisconsin); 4 in Italy; 3 in Germany; 2 each in Canada and
Japan; and, 1 each in Austria, Belgium, Brazil, England, France, Hungary,
Ireland, Israel, Mexico, Taiwan, Russia, Scotland, South Africa, Spain,
Sweden, and Switzerland.
2.4 | Echocardiography
Investigators were instructed to enter cats that had diagnostic-quality
2-dimensional, color flow Doppler, and M-mode echocardiographic
examinations performed in accordance with published standards.8,50,51
Diagnosis was based on information from all available tomographic
views including right parasternal long-axis 4-chamber, long-axis inflow-
outflow, and short-axis views, and left apical views. Cardiac measure-
ments were made from 2D echo-guided M-mode images from right
parasternal short-axis views by most investigators or, using 2D echo-
cardiography by several investigators. Left ventricular (LV) hypertrophy
was diagnosed when the thickest end-diastolic interventricular septal,
LV free wall segment or both measured 6 mm.8 The obstructive form
(HOCM) was defined for our study as LV hypertrophy with systolic
anterior motion of the mitral valve (SAM), coupled with diffuse LV out-
flow tract turbulence and peak systolic outflow velocity2.5 m/s.
Cases were not stratified according to LV outflow tract gradient.
Dynamic RV outflow tract obstruction was designated when maximal
RV outflow tract velocity was>1.6 m/s.52
2.5 | Data collection and outcomes assessment
Cats for which first diagnosis was made between November 2001 and
January 2011 were assessed during the study period, which extended
between January 2010 and January 2016. Data collection forms were
used by investigators to record pertinent demographic and health infor-
mation. This data included age at diagnosis, breed, body weight, labora-
tory, and echocardiographic information, physical examination and
laboratory findings, arrhythmias (assessed from ECG recording or from
simultaneous ECG trace during echocardiographic examination),
whether cardiovascular medications were prescribed, and outcomes
(CHF, ATE, and cardiovascular death). Outcomes assessments were
made by study investigators based on consideration of all available clin-
ical data. Serum thyroxine and creatinine concentrations and SBP
results that were recorded closest to date of diagnosis were included,
but were not available for every case. Cardiovascular mortality was
designated as death associated with CHF, ATE, euthanasia because of
these complications, or SD. Sudden death was defined as unanticipated
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death with absence of clinical signs or illness within 24 hours of last
being observed healthy, or occurring at least 7 days after resolution of
CHF.8 Morbidity and mortality dates were recorded from medical
records. When this data was not available, information was obtained
from the pet owner or attending veterinarian interview, assisted by a
medical questionnaire with standardized questions related to cardio-
vascular and noncardiac morbidity and mortality. Survival was calcu-
lated from initial diagnosis to date of death, last recorded examination,
or last contact.
2.6 | Statistical analysis
Power calculation to estimate study population size was guided by
results of prior studies,7,9 and a planned 5-year minimum follow-up
period. Based on these assumptions, 250 cats with preclinical hyper-
trophic cardiomyopathy and 250 AH were considered to provide 80%
power to detect a difference in survival proportions between preclinical
cardiomyopathy compared with AH, with a significance level (alpha) of
0.05.
Baseline descriptive statistics are reported as mean and standard
deviation for normally distributed variables and median (interquartile
range [IQR]) for non-normally distributed variables. The normality of
the residuals was judged by visual inspection. Between-groups analyses
of baseline variables were performed using analysis of variance
(ANOVA) or Kruskal-Wallis tests as appropriate according to the distri-
bution of residuals, using Holm-Sidak or Dunn’s test post-hoc analyses,
respectively, when indicated. Analyses for proportions of categorical
variables were performed using a Chi-Square or Fisher’s Exact analysis,
as appropriate. Univariate time-to-event survival analyses were per-
formed using Kaplan Meier product limit estimates. Survival range was
presented if median survival was not reached. Statistical differences
among strata were determined by log-rank test. Time-to-event survival
time analyses represented time from diagnosis to end-date. End-date
was defined as first instance of death, cardiovascular morbidity, or
being lost to follow-up, depending upon the analysis. Patients remain-
ing alive or lost to follow-up at study completion were right-censored.
A generalized linear model was used to calculate incidence for the
entire population and cohort level by age quartile expressed as rates as
per 1000 cat years, employing a Poisson distribution. Proportion at risk
was calculated using Kaplan Meier analysis. Patient population survival
variables were clinically defined and survival time was further assessed
at 1, 5, and 10 years after initial diagnosis, respectively. Death type or
TABLE 1 Demographic characteristics of feline study populations
Study Population Groups
Characteristic AH n5 722 HCM n5430 HOCM n5578
HCM/
HOCM n51008
AH
versus
HCM
AH
versus
HOCM
AH versus
HCM/
HOCM
Group Comparison P Values
Age, years
(Median; IQR)
4.9 (1.9-9) 7.4 (4–11) 5.7 (3–9) 6.5 (3–10) <.001 .013 <.001
Breed Number % Number % Number % Number %
Domestic Shorthair 304 42.1 265 61.6 353 61.1 618 61.3 <.001 <.001 <.001
Maine Coon 145 20.1 32 7.4 26 4.5 58 5.8 <.001 <.001 <.001
Domestic Longhair 38 5.3 45 10.5 35 6.1 80 7.9 .001 .620 .038
Persian 37 5.1 27 6.3 60 10.4 87 8.6 .487 <.001 .007
Norwegian Forest Cat 30 4.2 5 1.2 5 0.9 10 1.0 <.001 <.001 <.001
Siamese 24 3.3 11 2.6 6 1.0 17 1.7 .579 .011 .041
Sphynx 21 2.9 5 1.2 8 1.4 13 1.3 .083 .095 .026
Ragdoll 14 1.9 2 0.5 2 0.3 4 0.4 .071 .020 .004
Other 109 15.1 38 8.8 83 14.4 121 12.0 .003 .769 .072
Sex
Male Intact 97 13.4 39 9.1 41 7.1 80 7.9 .033 <.001 <.001
Male Neutered 264 36.6 268 62.3 372 64.4 640 63.5 <.001 <.001 <.001
Female Intact 159 22.0 25 5.8 21 3.6 46 4.6 <.001 <.001 <.001
Female Neutered 202 28.0 98 22.8 144 24.9 242 24.0 .061 .238 .057
Body weight, kg
(Median, IQR)
4.5 (3.6-5.4) 5.2 (4.2–6.0) 5 (4.2–6.0) 5 (4.2–6.0) <.001 <.001 <.001
Abbreviations: IQR, interquartile range; HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy; Other,
pedigree crosses and all other nonspecified breeds.
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comorbidity type was censored after 1, 5, and 10 years, respectively,
allowing for a cross-sectional view of the respective time points. Dura-
tion of event-free survival (EFS) comprised the time interval from the
date of study entry to the date of first cardiac morbidity (CHF or ATE).
Postevent survival (PES) comprised the time from the date of first CHF
or ATE morbidity to cardiac death from CHF, ATE, or SD. Additional
analyses included stratification at age quartile determined by age at
diagnosis. Because of varied study enrollment and study end dates,
mean between-cohort survival times estimated by univariate Kaplan
Meier method were used to calculate time to event for EFS and PES,
and compared by ANOVA. All analyses were carried out with SAS 9.4
(Cary, NC 2016) and deemed significant at P< .05.
3 | RESULTS
3.1 | Population characteristics at time of diagnosis
One-thousand seven-hundred thirty cats fulfilled entry criteria; 1008
(58.3%) had hypertrophic cardiomyopathy comprising 430 (24.9%)
HCM and 578 (33.4%) HOCM; and, 722 (41.7%) were AH (Table 1).
Apparently healthy cats were younger (median, 4.9 years; range, 0.5–
21 years) than HCM (median, 7.4 years; range, 0.5–20 years; P< .001)
and HOCM (median, 5.7 years; range, 0.5–19 years; P< .013); HOCM
were younger than HCM (P< .001). Ages recorded in 1006 of 1008
HCM/HOCM cats clustered predominantly at 1–5 years and 5–11
years, but the proportion markedly decreased after 11 years of age
(Figure 1). Twenty-seven percent were10 years of age and 10%
were 13–20 years of age. Body weight in HCM and HOCM cats did
not differ (P5 .095), but was slightly higher compared with AH (both
P< .001; Table 1). The overall study population included 34 breeds,
most commonly Domestic Shorthair, Main Coon Cat, Persian, Domestic
Longhair, and Norwegian Forest Cat (Table 1, Figure 2). Less commonly
represented breeds included Abyssinian, American Shorthair, Bengal,
Birman, Bombay, British Shorthair, Burmese, Chartreux, Cornish Rex,
Devon Rex, Egyptian Mau, European Shorthair, Exotic Shorthair,
Havana Brown, Himalayan, Manx, Oriental Shorthair, Pixie-bob, Rag-
doll, Russian Blue, Scottish Fold, Selkirk Rex, Siamese, Somali, Sphynx,
Turkish Angora, and Turkish Van. The prevalence of both intact and
neutered males was significantly higher in HCM and HOCM than AH.
Comparing HCM and HOCM cohorts, the proportions of intact males
and neutered males did not differ significantly (P5 .303 and P5 .589,
respectively). The proportion of neutered females did not differ signifi-
cantly between HCM and HOCM (P5 .480). Intact females repre-
sented a very small proportion of HCM and HOCM compared with AH
cats (Table 1).
Systolic heart murmurs were detected commonly (Table 2). Murmur
prevalence was higher in HCM/HOCM (82.4%) than AH (46.4%;
P< .001). Moderate to loud (grade 3–5/6) systolic murmurs were more
common in HCM/HOCM (58.8%) than AH (14.8%; P< .001), and in
FIGURE 1 Age distribution for 1006 of the 1008 cats with
obstructive and nonobstructive hypertrophic cardiomyopathy
recorded at the time of diagnosis. In 2 cats, age was not recorded
FIGURE 2 Most prevalent breeds in feline study populations.
HCM, nonobstructive hypertrophic cardiomyopathy; HOCM,
obstructive hypertrophic cardiomyopathy
TABLE 2 Prevalence of systolic heart murmurs in feline study populations
Study Population (n51730) P values
AH (n5722) HCM (n5430) HOCM (n5578)
HCM/HOCM
(n5 1008)Number of
cats with
heart murmurs 335 % 46.4 294 % 68.4 537 % 92.9 831 % 82.4
AH
versus
HCM
AH
versus
HOCM
AH
versus
HCM/
HOCM
Heart murmur grade
1 60 8.3 25 5.8 13 2.3 38 3.8 .028 <.001 <.001
2 168 23.3 109 25.3 91 15.7 200 19.8 .465 .007 .078
3 91 12.6 120 27.9 271 46.9 391 38.8 <.001 <.001 <.001
4 16 2.2 39 9.1 157 27.2 196 19.4 <.001 <.001 <.001
5 0 0.0 1 0.2 5 0.9 6 0.6 .195 .012 .038
Abbreviations: HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy.
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HOCM (74.9%) compared with HCM (37.2%) cats (P< .001), respec-
tively. Soft systolic murmurs (grades 1–2/6) were more common in AH
(31.6%) than HCM/HOCM (23.6%) cats (P< .001). Dynamic RV outflow
tract obstruction was recorded in 43 (10%) HCM cats (of which 39 had
soft to moderately loud systolic murmurs), and in 80 (13.8%) HOCM
cats. Gallop sounds were recorded in 48 (11.2%) HCM compared with
40 (6.9%) HOCM cats (P5 .025). Heart rate (median; IQR) during physi-
cal examination at study entry was lower in AH (180; 167–200 beats
per minute [bpm]) compared with HOCM (190; 170–210 bpm; P 5
.001), but did not differ between HCM (186; 167–202 bpm) and AH
(P5 .676), or between HCM and HOCM (P5 .164).
Arrhythmias were recorded in 128/1008 (12.7%) HCM/HOCM
cats. These included supraventricular tachycardia (n54), atrial fibrilla-
tion (n56), atrial premature complexes (APCs, n517), isolated ventric-
ular premature complexes (VPCs, n573), and 1 cat each with
ventricular bigeminy and nonsustained ventricular tachycardia. Bradyar-
rhythmias included first-degree atrioventricular block (n52) and high
grade atrioventricular block (n52). Conduction abnormalities detected
from ECG recordings included left anterior fascicular block (LAFB) in 16
(4 HCM, 12 HOCM), right bundle branch block (RBBB; n54) and 1 cat
each with ventricular pre-excitation and left bundle branch block.
Arrhythmias recorded in 30 (4.2%) AH were isolated VPCs (n522),
LAFB (n55), and RBBB (n53).
Systolic blood pressure (median; IQR) did not differ among AH
(140; 120–150 mm Hg), HCM (140; 120–150 mm Hg), and HOCM
(135; 120–150 mm Hg; P5 .168) cohorts.
One or more cardiovascular drugs (beta-adrenoceptor blockers,
angiotensin converting enzyme inhibitors, diltiazem hydrochloride, aspi-
rin, or clopidogrel) were prescribed in 52.3% HCM and 78.2% HOCM
(P< .001), but not in AH. No additional information regarding dosage,
compliance, or duration was recorded.
3.2 | Incidence and risk for cardiovascular morbidity
and mortality
Cardiovascular morbidities were recorded in 307 (30.5%) of 1008
HCM/HOCM cats comprising 361 events and in 7 (0.97%) AH (Table 3).
The proportion of CHF events did not differ between HCM (106/
430) and HOCM (138/578; P5 .834), nor did ATE events differ in
HCM (41/430) compared with HOCM cats (76/578; P5 .094). Simi-
larly, HCM and HOCM did not differ with respect to time from study
entry to development of CHF (P5 .216) or ATE (P5 .188; Figure 3).
The proportion of syncopal events was not different between HCM
(n59, 2.1%) and HOCM (n514, 2.4%; P50.838). Syncope was
recorded in 2 (0.28%) AH.
TABLE 3 Cardiovascular morbidity and mortality in feline study populations
Study Population Groups
AH HCM HOCM HCM/HOCM
n5 722 n5430 n5 578 n51008
Cardiovascular
morbidity
Number
events % Normal
Number
events % HCM
Number
events % HOCM
Number
events
% HCM/
HOCM
CHF 6 0.83 106 24.7 138 23.9 244 24.2
ATE 5 0.69 41 9.5 76 13.2 117 11.6
Sudden death 0 0 9 2.1 13 2.3 22 2.2
All cardiovascular death 7 0.97 115 26.7 166 28.7 281 27.9
Abbreviations: ATE, arterial thromboembolism; CHF, congestive heart failure; HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive
hypertrophic HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy.
FIGURE 3 Kaplan-Meier survival curves estimating percentage of
430 cats with nonobstructive (HCM) compared with 578 cats with
the obstructive (HOCM) form of hypertrophic cardiomyopathy that
have not yet experienced morbidity (Y-axis) from CHF (top) or ATE
(bottom) against time (X-axis)
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3.2.1 | Incidence
The incidence of CHF, ATE, SD, and all-cardiovascular death events per
1000 cat years for each cohort was delineated by quartiles correspond-
ing with age at the time of study entry (group 1,<2.5 years; group 2,
2.5-5.6 years; group 3,>5.6–10 years; group 4, >10 years; Table 4). In
the HCM/HOCM population, CHF incidence was 24.8% higher in
cats>10 years of age compared to cats<2.5 years of age (68.1 events
versus 51.2 events per 1000 cat years, respectively). The incidence of
ATE increased from the first to the third age quartile (from 22.5 to
32.7 events per 1000 cat years, respectively), and then decreased
sharply to 18.4 events per 1000 cat years in cats>10 years of age.
Incidence of cardiovascular death was 57.1 events per 1000 cat years
TABLE 4 Incidence of cardiovascular morbidity and mortality events per 1000 cat years grouped by age at study entry
Age group Population cohorts CHF morbidity ATE morbidity Sudden death All-cardiovascular death
Total Population AH 1.6 1.3 0 1.8
HCM 62.9 22.2 4.6 64.8
HOCM 54.2 29.5 5.3 62.5
HCM/HOCM 57.6 26.6 5.0 63.4
Group 1 (<2.5 years) AH 0.7 0.7 0 0
HCM 52.6 11.7 2.9 46.7
HOCM 50.4 28.3 6.3 62.7
HCM/HOCM 51.2 22.5 5.1 57.1
Group 2 (2.5-5.6 years) AH 2.3 0 0 1.1
HCM 55.1 22.8 8.2 55.5
HOCM 57.8 31.0 3.6 59.1
HCM/HOCM 56.8 28.0 5.3 57.7
Group 3 (>5.6–10 years) AH 2.4 2.4 0 4.7
HCM 62.6 33.1 1.8 78.8
HOCM 53.4 32.4 6.1 69.9
HCM/HOCM 57.1 32.7 4.4 72.7
Group 4 (>10 years) AH 2.0 3.9 0 3.9
HCM 81.4 15.3 5.0 75.1
HOCM 54.4 21.7 5.3 53.6
HCM/HOCM 68.1 18.4 5.1 64.7
Abbreviations: ATE, arterial thromboembolism; CHF, congestive heart failure; HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive
hypertrophic cardiomyopathy.
TABLE 5 Risk of cardiac morbidity and death assessed at 1, 5, and 10 year intervals after study entry
CHF ATE Sudden Death All-Cardiovascular Death
% Population
remaining
at-risk
% Population
affected
% Population
remaining
at-risk
% Population
affected
% Population
remaining
at-risk
% Population
affected
% Population
remaining
at-risk
% Population
affected
Risk
1-year post diagnosis
AH 100 0.0 100 0.0 100 0.0 100 0.0
HCM 93.3 6.7 95.8 4.2 99.3 0.7 92.3 7.7
HOCM 92.7 7.3 97.1 2.9 99.1 0.9 94.1 5.9
HCM/HOCM 93.0 7.0 96.5 3.5 99.2 0.8 93.3 6.7
5-years post diagnosis
AH 99.6 0.4 99.6 0.4 100 0.0 99.3 0.7
HCM 79.5 20.5 92.3 7.7 98.1 1.9 77.7 22.3
HOCM 80.4 19.6 88.7 11.3 96.7 3.3 76.8 23.2
HCM/HOCM 80.1 19.9 90.3 9.7 97.3 2.7 77.2 22.8
10-years post diagnosis
AH 99.2 0.8 99.3 0.7 100 0.0 99.0 1.0
HCM 75.6 24.4 91.2 8.8 97.4 2.6 73.3 26.7
HOCM 76.5 23.5 86.8 13.2 96.0 4.0 70.6 29.4
HCM/HOCM 76.1 23.9 88.7 11.3 96.6 3.4 71.7 28.3
Abbreviations: ATE, arterial thromboembolism; CHF, congestive heart failure; HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive
hypertrophic cardiomyopathy.
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for cats<2.5 years of age, and was unchanged (57.7 events per 1000
cat years) between 2.5 and 5.6 years of age. A higher incidence of car-
diovascular death was recorded in older age quartiles. In contrast, the
overall incidence of CHF or ATE in AH at initial diagnosis was 1.6 and
1.3 events per 1000 cat years, respectively.
3.2.2 | Risk
The risk of cardiovascular morbidity and mortality for HCM, HOCM,
and HCM/HOCM cohorts increased progressively at 1, 5, and 10-year
intervals after study entry, as well over age quartiles (Table 5, Figure 4).
Of the 1008 cats with preclinical HCM/HOCM, the risk for CHF and
ATE morbidity and all-cardiovascular death was approximately 3 times
greater at 5 years compared with 1 year after initial diagnosis. Overall,
the risk of all-cardiovascular death for HCM/HOCM was approximately
1 in 15, 1 in 4.4, and 1 in 3.5 as calculated at 1, 5, and 10-year time
points, respectively. Overall risk of all cardiovascular death in AH was
1 in 100 (Table 5 and Figure 4).
3.3 | Survival analyses-mortality
Cardiovascular death was recorded in 281 (27.9%) of 1008 HCM/
HOCM cats (115 of 430 with HCM [26.7%], 166 of 578 with HOCM
[28.7%]; Table 3). Sudden death comprised 22 of these 281, a 2.2%
prevalence in the 1008 cats. Seven deaths were attributed to cardio-
vascular death in the 722 AH (1.0%). Cardiovascular survival (median,
range) was significantly shorter in HCM/HOCM (10.9 years; 3 days-3.1
years) than AH (not estimable [NA] due to low event rate; 6 days-14.1
years; P< .0001; Figure 5). The oldest 10% of surviving HCM/HOCM
cats at study end were 9–14.7 years of age. Cardiovascular survival
was not significantly different between HCM (10.9 years; 2 days-12.5
years) and HOCM (NA; 3 days-13.1 years) over time (P5 .873; Figure 6).
Furthermore, no significant difference was found between HCM and
HOCM populations for the overall proportion of cardiovascular death
(P5 .535), proportion of cardiovascular death associated with CHF
(P5 .834), and proportion of cardiovascular death associated with ATE
(P5 .118). The proportions of SD did not differ between HCM and
HOCM cats (P5 .960). Time (median, IQR) from study entry to SD did
not differ significantly between HCM (1290 days; 304–2176 days) and
HOCM (1156 days; 457–1777 days; P5 .676). Furthermore, time from
onset of CHF or ATE morbidity to cardiovascular death did not differ
between HCM and HOCM populations (P5 .489 and P5 .578, respec-
tively; Figure 7). Cardiovascular survival did not differ significantly among
age quartiles within HCM (P5 .206) or in HOCM (P5 .796) populations.
Cardiovascular survival did not differ significantly between HCM cats
that had SBP measured compared with HCM cats that did not have SBP
measured (P5 .085); HOCM cats that had SBP measured compared with
HOCM cats that did not have SBP measured (P5 .255); HCM compared
with HOCM that had SBP recorded (P5 .476); or between these cohorts
that did not have SBP recorded (P5 .609). In addition, cardiovascular sur-
vival did not differ significantly between HCM/HOCM cats that had
serum thyroxine concentrations measured compared with HCM/HOCM
cats that did not have serum thyroxine concentrations measured
(P5 .263). Cardiovascular survival in HCM/HOCM cats did not differ sig-
nificantly between those prescribed or not prescribed1 cardiovascular
medications at study entry (P5 .845).
3.4 | Time to event, event-free, and PES analysis
3.4.1 | Time to event
Congestive heart failure and ATE morbidities occurred individually or
together. In HCM: CHF occurred without ATE in 90 cats (median, 57
days; range, 2–2954 days); ATE occurred without CHF in 25 cats
(median, 370 days; range, 5–3993 days); and, both CHF and ATE
occurred in 16 cats (concurrently in 10 cats [median, 513 days; range,
4–3353]; ATE preceded CHF in 3 [1775, 2384, and 3334 days]; and
CHF preceded ATE in 3 [1178, 1316, and 2409 days]). In HOCM: CHF
occurred without ATE in 98 cats (median, 1017 days; range, 4–4029
days); ATE occurred without CHF in 36 cats (median, 1081 days; range,
1–2518 days); and both CHF and ATE were recorded in 40 cats (con-
currently in 20 [median, 790 days; range, 11–2151 days]; ATE preceded
CHF in 14 [median, 1184 days; range, 3–2980 days]; and CHF preceded
ATE in 6 [median, 933 days; range, 177–2075 days]). In AH: CHF
occurred without ATE in 5 cats (median, 1633 days; range, 841–2749
FIGURE 4 Percentage of 1008 cats with nonobstructive (HCM,
n5430) and obstructive (HOCM, n5578) hypertrophic
cardiomyopathy at risk for cardiovascular mortality, by age quartile
when diagnosed and assessed 1, 5, and 10 years after study entry.
Q, age quartile; yrs., years
FIGURE 5 Kaplan-Meier survival curves estimating percentage of
1008 cats with nonobstructive (HCM, n5430) and obstructive
(HOCM, n5578) forms of hypertrophic cardiomyopathy that have
not yet experienced cardiovascular death (Y-axis) compared with
722 AH against time (Y-axis). NA, median not estimable
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days, both CHF and ATE developed in 1 cat, and ATE occurred without
CHF in 4 cats (median, 1760 days; range, 387–2819 days). Two of the
5 AH with CHF without ATE had developed hyperthyroidism.
3.4.2 | Event-free survival
Of the 1008 HCM/HOCM cats, 307 (30.5%) developed CHF, ATE or
both, whereas 281 (27.9%) experienced cardiovascular death (22 of the
281 [7.8%] were SD). Event-free survival was calculated for the 259
cats that died from CHF, ATE or both. Of these 259 cats, 140 (54.1%)
died or were euthanized on the day of their first recorded CHF or ATE
morbidity, whereas 119 (45.9%) cats survived past the day of recorded
morbidity and subsequently died of their cardiovascular disease. Event-
free survival (mean6 standard deviation) did not differ significantly
between the cohort of 140 cats (2.962.2 years) compared with the
cohort of 119 cats (2.462.11 years; P5 .101; Figure 8).
3.4.3 | Post-event survival
Post-event survival (the time from onset of CHF or ATE to cardiovas-
cular death) calculated for the 119 cats that survived>1 day after CHF
or ATE had occurred was 1.361.7 years, significantly shorter than
both the EFS for this cohort (P< .0001), and for EFS of the cohort of
140 cats that died on the day of their first cardiovascular morbidity
(P< .0001; Figure 8). Moreover, PES in these 119 cats did not differ
significantly with respect to age quartiles (P5 .402) or between HCM
and HOCM cats that comprised this cohort (P5 .364).
4 | DISCUSSION
REAL is the first international, collaborative, epidemiologic study to
evaluate populations of preclinical feline hypertrophic cardiomyopa-
thy and AH. Intending to identify and compare long-term cardiovas-
cular incidence, risk, and survival, REVEAL documented the natural
history of cats living in geographically diverse environments, in 21
countries, and across 5 continents. In this population, the incidence
of cardiovascular morbidity and mortality in affected cats was
FIGURE 8 Kaplan-Meier survival curves estimating the EFS
proportion and PES proportion (Y-axis) against time (X-axis). Event-
free survival group-A comprised a cohort of 140 cats with preclini-
cal hypertrophic cardiomyopathy who died on the day of their first
recorded CHF/ATE morbidity. Event-free survival group-B com-
prised a cohort of 119 cats with preclinical hypertrophic cardiomy-
opathy who survived more than one day after their first recorded
CHF/ATE morbidity. Postevent survival was calculated for these
119 cats. *P5 .101; **P< .0001; SD, standard deviation
FIGURE 7 Kaplan-Meier survival curves estimating the percentage
of 430 cats with nonobstructive (HCM) compared with 578 cats
with obstructive (HOCM) hypertrophic cardiomyopathy that have
not yet experienced cardiovascular death (Y-axis) for CHF (A), or
ATE (B) against time (X-axis). NA, median not estimable
FIGURE 6 Kaplan-Meier survival curves estimating percentage of
430 cats with nonobstructive (HCM) compared with 578 cats with
the obstructive form (HOCM) of hypertrophic cardiomyopathy that
have not yet experienced cardiovascular death (Y-axis) against time
(X-axis). NA, median not estimable
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substantial. Of the cohort of 1008 HCM and HOCM cats, nearly
one-third developed CHF, ATE, or both and slightly more than
one-quarter experienced cardiovascular death. In contrast, cardio-
vascular death occurred in 1% of AH. Preclinical hypertrophic
cardiomyopathy therefore may be regarded as a global disease that
confers reasonably high risk and denotes a major negative prognos-
tic indicator for cardiovascular mortality.
Notably, cardiovascular morbidity, mortality, and survival did not
differ significantly between obstructive (HOCM) and nonobstructive
(HCM) forms of feline hypertrophic cardiomyopathy, reinforcing the
clinical impression that dynamic LV outflow tract obstruction (LVOTO)
is not a predictor of adverse outcome.16,18 This finding diverges from
the idea that LVOTO carries high risk for progressive heart failure and
the cardiac debilitation that characterizes HOCM in human
patients.39,43–48
Reports comparing cardiovascular survival between preclinical
feline HCM and HOCM have been sparse, conflicting, and confined to
small cohorts.8,17 The REVEAL study demonstrated no significant dif-
ference in cardiovascular morbidity or survival between HCM and
HOCM and should thus help resolve this debate. In reality, the notion
that HOCM conferred proportionately higher risk was shaped by the
dominance of human literature reporting poor outcomes associated
with LVOTO and increased gradients.39–41 Echocardiography played an
important role in this observation. Its introduction by the early 1970s
simplified detection and characterization of cardiomyopathy in human
patients, and was paralleled a decade later in veterinary medicine. In
addition, echocardiography facilitated recognition of systolic anterior
motion of the mitral valve (SAM) and LVOTO, characteristics of the
obstructive form (HOCM) of this disease. Insofar as common clinico-
pathologic features shared by humans and cats with hypertrophic
cardiomyopathy were known,2,4,8,15,21 and in the absence of epidemio-
logic data in cats, dynamic LVOTO became regarded as a target vari-
able for treatment in veterinary medicine.17,49 Our study contributes a
fresh clinical perspective to the natural history of preclinical hyper-
trophic cardiomyopathy and counters this former perception.
One possible explanation why clinical outcomes did not differ sig-
nificantly between populations with obstructive (HOCM) and nonob-
structive (HCM) disease in our study is that these designations may
represent more of a functional continuum than distinct, separate enti-
ties. In humans affected with the nonobstructive form (HCM), a pro-
portion will develop LVOTO from SAM, mid-ventricular contact or
both after physiologic challenge induced by drugs or exercise. This find-
ing supports the concept that hypertrophic cardiomyopathy is predomi-
nantly a disease of LVOTO.42 Indeed, the fact that LVOTO can be
provoked in the cat6 lends endorsement for this hypothesis. It also
adds an element of ambiguity to the classification of this disease. If
LVOTO was provoked as a result of stress-induced sympathetic tone
during echocardiographic examination, such cats would be categorized
as “obstructive” (HOCM), and yet may have been nonobstructive
(HCM) under normal or baseline living conditions. In other cases, the
rapid heart rate and relatively small LV end-systolic chamber of cats
can challenge the detection of SAM, or render uncertain the distinction
between obstructive and nonobstructive forms of this disease. Thus,
SAM could have been present but missed in some cats diagnosed with
the nonobstructive (HCM) form.
The REVEAL study found that CHF incidence increased slightly
from youngest to oldest age, whereas ATE incidence increased up
through the third age quartile, but became less common after the age of
10 years. Risk for CHF, ATE, and cardiovascular death increased over
time and age. Moreover, the risk of cardiovascular death for each age
quartile was progressively higher at 5 and 10 years compared with 1
year after diagnosis for each age quartile. In AH the risk of cardiovascu-
lar death was only 1%. In preclinical HCM and HOCM, sudden death
was substantially lower in our present study than described from mixed
preclinical and clinical feline populations.8,9,18,25,28 Sudden death is a
well-known manifestation of hypertrophic cardiomyopathy in humans,
especially in high risk subgroups.46–48
Early onset of preclinical HCM or HOCM, defined as occurring in
cats<1 year of age was approximately 3% in the HCM/HOCM cohort
in our study. Other reports of early onset vary widely based on cut-off
values used to define LV end-diastolic wall thickness.10,12,24,28,37 Age of
hypertrophic cardiomyopathy associated with cardiovascular death has
been reported in certain breeds, including young, highly inbred Maine
Coon cats, particularly in litters where affected individuals were mated.24
In addition, Ragdoll cats homozygous for the MYBPC3 R820W mutation
died at a younger age and cardiovascular survival was shorter compared
to heterozygous or wild types,32 and onset of CHF before 1 year of age
has been observed in this breed.53 Others have reported that the age at
which cardiovascular morbidity developed was younger in Maine Coon
than Persian, DSH, Sphynx, and Chartreux breeds combined.28
Preclinical HCM/HOCM in our study was diagnosed most com-
monly between 1 and 11 years of age, and the proportion decreased
sharply thereafter. Others have reported wide age variability from
pooled preclinical and clinically affected populations.7–9,12,18,25,26,54
Of the HCM/HOCM cats that developed CHF or ATE, the mean
EFS did not exceed 3 years. In addition, EFS did not differ significantly
between HCM and HOCM populations. Thus, once affected cats devel-
oped cardiovascular morbidity, the trajectory of PES from onset of clini-
cal signs to cardiovascular death was rapid, averaging just 1.3 years.
Although hypertrophic cardiomyopathy has been held to presage
decreased survival, REVEAL found that a proportion of affected cats
survived into their second decade. Similar findings have been reported
in selected pedigrees in which nearly one-third were 10–15 years of
age and approximately 5% were>15 years of age.28 This finding indi-
cates that preclinical hypertrophic cardiomyopathy can be compatible
with normal life expectancy. Prolonged survival with this condition has
been increasingly reported in affected humans.46
The HCM/HOCM population’s high male prevalence, dominated
by neutered males, was similar to previously reported male predilection
rates of between 63% and 79%.7,9,13,17,18 Heart murmurs were com-
mon in both AH as well as HCM/HOCM cats. Similar findings have
been reported by others.4,5,9,13,16–18,26–28 The true prevalence of heart
murmurs in AH is uncertain, however, because reported prevalence
likely is affected by referral bias. The comparatively higher prevalence
of heart murmurs and louder grades of murmurs in cats with HOCM
may have provided an opportunity during physical examination to
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detect heart disease earlier compared with cats with HCM, accounting
for the slightly younger HOCM cohort. Arrhythmias were detected at
study entry in approximately 13% of preclinical HCM/HOCM and in
4% of AH. Others have reported arrhythmias from mixed preclinical
and decompensated cohorts.5,7–9,13,16,25,28
The pervasiveness of hypertrophic cardiomyopathy in the general
feline population is unknown. Estimation of disease has inherent limita-
tions including small sample size, single-site data source, selection and
referral bias, skewed age and breed composition, and diagnostic verifi-
cation. Additional weaknesses are imposed by lack of veterinary con-
sensus guidelines for echocardiographic measurement technique and
diagnostic cut-off values. Within this context, prevalence of feline
hypertrophic cardiomyopathy has been reported. When investigators
applied >5.5 mm or >6 mm diagnostic cut-off values and different
measurement techniques to a cohort of 92 cats screened by echocardi-
ography, prevalence ranged from 12% to 51% in this cohort.27 Preva-
lence reported by others using6 mm cut-off was 14.7% in 780 cats
screened at rehoming shelters in southeastern England,13 14.6% in 103
cats screened in western Virginia,6 and 8.3% of 144 cats screened in
Switzerland.10 Two additional studies using5.5 mm cut-off reported
8.5% in 329 British shorthair cats in Denmark12 and 25% in 53 Norwe-
gian Forest cats screened in London.35 Recently, echocardiographic ref-
erence ranges based on allometric scaling have been proposed.54,55
United States pet ownership surveys identify steady growth in the
feline pet population, estimating 74 million cats in 2012 (AVMA, U.S.
Pet Ownership & Demographics Sourcebook, 2012) and 94.2 million
cats between 2017 and 2018 (2017–2018 APPA National Pet Owners
Survey http://americanpetproducts.org/pubs_survey.asp). Recently,
estimates of hypertrophic cardiomyopathy prevalence in humans sug-
gests that 1 out of 200 individuals (0.5%) is genetically affected,56
with a substantial proportion being genetically positive but phenotypi-
cally negative. If the prevalence of feline hypertrophic cardiomyopathy
were conservatively extrapolated at 0.5% based on findings reported in
humans,56 upwards of 470 000 cats could be affected in the United
States of America. Alternatively, if 8% prevalence was inferred based
on the lowest reported veterinary estimate that applied an echocardio-
graphic cut-off value6 mm,10 approximately 7.5 million cats could be
affected in the United States of America alone.
Our study has some limitations. Study cases originated from refer-
ral centers, and therefore demographics could have been subject to
referral bias. However, the large study populations encompassing wide
and varied geographical regions may have diminished this effect. Appa-
rently healthy cats were significantly younger compared to HCM and
HOCM cohorts. Arterial blood pressure, creatinine, and T4 data were
available for a substantial number of cats with hypertrophic cardiomy-
opathy. Close attention was paid to the medical history and physical
examination in order to exclude any cases with clinical findings indica-
tive of systemic illness or disease. However, some cats with subclinical
azotemia, increased serum thyroid hormone concentration, or
increased SBP, may have been missed and inadvertently included in
the HCM/HOCM cohort. In such cases, it was not possible to verify
whether LV hypertrophy was associated solely with hypertrophic car-
diomyopathy, with abnormal loading conditions, or was present in
conjunction with comorbidities. In HCM/HOCM cats 10 years of age
representing greater age-related risk for comorbidities, SBP and or cre-
atinine data were available in approximately 85%, and T4 data were
available in approximately half of the cases. Although the REVEAL
study found that preclinical hypertrophic cardiomyopathy and associ-
ated cardiovascular morbidity and death are global feline health issues,
it did not test for potential regional differences in cardiovascular inci-
dence and risk. In diagnosing hypertrophic cardiomyopathy and AH,
cardiac status was based on a single initial echocardiographic examina-
tion designating the point of study entry. Potential remodeling over
time was not assessed, but theoretically could have affected outcome
or diagnosis in some cases, or been affected by age-related penetrance
of the hypertrophic cardiomyopathic phenotype. The thickest LV wall
segment was selected to diagnose LV hypertrophy, but may not by
itself have represented the pathophysiologic and clinical heterogeneity
of this disease. Echocardiograms were not reviewed centrally, which
would have exceeded financial and logistical resources. Nonetheless,
echocardiographic diagnoses were reviewed by board-certified cardiol-
ogists or veterinarians who practice cardiology. Systolic anterior motion
of the mitral valve and LVOTO could have been over-diagnosed in
some cats in response to stress-induced exaggerated systolic chamber
function, and such cats may not have had SAM and LVOTO under nor-
mal home conditions. Response to provocative measures were not con-
sidered as a diagnostic criterion in our study, but may have induced
SAM and LVOTO in some cats exposed to these measures. However,
such procedures are not currently performed as part of routine, stand-
ard echocardiographic examination in cats. Cats with HOCM were not
subcategorized based on estimated LV outflow tract gradient. Thus, it
was not possible to determine whether a subset of cats with high gra-
dients is at higher cardiovascular risk. Although we attempted to
exclude cats with known underlying diseases in preclinical hypertrophic
cardiomyopathy and AH cohorts, some may have had undiagnosed or
preclinical conditions. A standardized medical questionnaire was used
to aid data collection when interviewing clients and referring veterinar-
ians, but some details may have been incorrectly remembered or
missed. Assessment of treatment compliance and potential drug effects
was not possible in this retrospective study.
5 | CONCLUSIONS
Data from the REVEAL study demonstrates that preclinical feline
hypertrophic cardiomyopathy is a global health concern that imposes
considerable risk for CHF and ATE morbidity, and substantially impacts
cardiovascular health over time. Indeed, cardiovascular morbidities
were recorded in nearly one-third and cardiovascular-related death
occurred in approximately 30% of the 1008 cats with HCM and
HOCM. There was no statistically significant difference between
obstructive (HOCM) and nonobstructive (HCM) forms of hypertrophic
cardiomyopathy regarding cardiovascular morbidity or mortality, time
from diagnosis to development of morbidity, or cardiovascular survival.
Collectively, these epidemiologic data highlight cardiovascular risks
associated with preclinical hypertrophic cardiomyopathy, and
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underscore the need to identify and develop health care and treatment
strategies that optimize monitoring, decrease risk, and improve
outcome.
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